PFA has revolutionized AF treatment through its tissue selectivity, safety, and procedural efficiency. Yet, early-generation systems using microsecond pulses face key challenges-excessive muscle stimulation, reliance on general anesthesia, and risks like hemolysis and gas embolism-that limit broad adoption.

As the world's first and only commercially available nanosecond PFA system, NxPFATM represents the "Next of PFA" generation. It combines the MaviPulseTM high repetition frequency ns-PFA console with the InteShotTM basket-shaped catheter to deliver irreversible electroporation of cardiomyocytes via high-voltage nanosecond pulses, effectively overcoming key limitations of microsecond PFA (μs-PFA) technologies:

Significantly reduces neuromuscular stimulation, enabling procedures under conscious sedation, improving patient comfort and lowering anesthesia risks;

Combines nanosecond pulses with a basket-shaped catheter to ensure optimal electrode-tissue contact and high success rates, while shortening procedural time;

Substantially lowers intravascular gas formation, lowering the risk of stroke or systemic embolism;

Minimizes erythrocytic damage and post-procedural bilirubin elevation, reducing potential kidney injury.

NxPFATM Demonstrates Outstanding Efficacy and Safety

The NxPFA TM system has been clinically validated through the SCENA-AF multicenter registration trial, which enrolled 166 patients with paroxysmal atrial fibrillation. The data has been acknowledged by NMPA and will soon be published in an academic journal. Key outcomes include:

100% acute pulmonary vein isolation success rate

88.27% one-year treatment success rate (PPS)

No device-related serious adverse events reported

Over 92.8% of procedures completed under conscious sedation, with excellent intraoperative tolerance.

These results confirm NxPFA TM 's strong performance in efficacy, safety, efficiency, and patient comfort. It remains the only PFA system globally to achieve one-shot PVI under conscious sedation with high success, marking the debut of the third-generation nanosecond PFA era.

"NxPFA TM 's approval is not only a major milestone for Pulsecare Medical but also a transformative breakthrough for cardiac electrophysiology. With NxPFA TM , we address critical clinical challenges and look forward to collaborating with global EP experts to shape the future of arrhythmia treatment-delivering smarter tools to physicians and safer, more effective, more comfortable therapies to patients," said Dr. Javen Tan, CEO of Pulsecare Medical.

About PulseCare Medical

Founded in July 2021 and headquartered in Shenzhen, Pulsecare Medical is dedicated to the innovation and development of cardiovascular multimodal therapeutic devices. Backed by a rare cross-disciplinary team combining clinical and engineering expertise, the company is building a next-generation energy platform for interventional therapies. Pulsecare offers total solutions for cardiac electrophysiology and hypertension interventional therapy, aiming to lead in minimally and non-invasive treatments.

Photo -

MENAFN04082025003732001241ID1109882360